GlassScriptPhysician profile
Dea Kurtovic
NPI 1528498771
$1,994.48
in general payments reported to CMS, 2019-2025
25 companies · $811 in 2025
The $811 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.95 · 2022: $288 · 2023: $384 · 2024: $444 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $394.25 | 2022-2025 | Darzalex, Imbruvica, Talvey |
| Merck Sharp & Dohme LLC | $224.75 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $162.05 | 2022-2025 | Jakafi, Niktimvo |
| Agios Pharmaceuticals, INC. | $144.06 | 2025 | Pyrukynd |
| Tempus Ai, INC | $143.58 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $142.97 | 2022-2023 | Tagrisso |
| Genentech USA, INC. | $132.61 | 2024-2025 | Tecentriq, Tecentriq Hybreza |
| E.R. Squibb & Sons, L.L.C. | $101.69 | 2022-2025 | Opdivo |
| Dendreon Pharmaceuticals LLC | $66.01 | 2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $53.11 | 2022-2024 | |
| Genzyme Corporation | $43.94 | 2024-2025 | |
| Puma Biotechnology, INC. | $41.96 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2024 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $32.25 | 2025 | Somatuline Depot, Onivyde |
| Beone Medicines USA, INC. | $28.82 | 2025 | Brukinsa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $28.41 | 2025 | Braftovi, Mektovi, Lorbrena |
| Rigel Pharmaceuticals, INC. | $28.20 | 2023 | Rezlidhia, Tavalisse |
| Immunogen, INC. | $27.88 | 2023 | Elahere |
| Daiichi Sankyo INC. | $25.41 | 2022 | |
| Lilly USA, LLC | $24.32 | 2024 | Verzenio, Jaypirca |
| Amgen INC. | $24.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.57 | 2025 | |
| Myriad Genetic Laboratories, INC. | $22.01 | 2024 | Myrisk |
| Astellas Pharma US INC | $21.64 | 2022 | |
| Seagen INC. | $19.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dea Kurtovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.